Drug Profile
HER2 cancer vaccine - BioLife Science
Alternative Names: Her VAXX; HER-Vaxx; IMU-131; PEV 6A; PEV6Latest Information Update: 18 Dec 2023
Price :
$50
*
At a glance
- Originator BioLife Science; Pevion Biotech
- Developer Imugene; Pevion Biotech
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
- Mechanism of Action ERBB 2 receptor antagonists; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Adenocarcinoma; Gastric cancer; Oesophageal cancer
- No development reported Breast cancer
Most Recent Events
- 20 Oct 2023 Updated immunogenicity data from a phase I/II HERIZON trial on gastric cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
- 28 Jun 2023 Updated immunogenicity data from the phase Ib/II HERIZON trial in Gastric cancer presented at the 25th World Congress on Gastrointestinal Cancer (WCGC-2023)
- 17 Aug 2022 Phase-II clinical trials in Adenocarcinoma (Combination therapy, Late-stage disease, Metastatic disease) in Australia (IM) (NCT05311176)